Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients With Uncontrolled Blood Pressure
Conditions
Interventions
Placebo
IONIS-AGT-LRx
Locations
50
United States
Pinnacle Research Group
Anniston, Alabama, United States
Central Research Associates, Inc.
Birmingham, Alabama, United States
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Cahaba Research, Inc.
Pelham, Alabama, United States
Syed Research Consultants LLC
Sheffield, Alabama, United States
Cardiology and Medicine Clinic
Little Rock, Arkansas, United States
Start Date
April 28, 2021
Primary Completion Date
June 29, 2022
Completion Date
October 3, 2022
Last Updated
February 18, 2025
NCT05746039
NCT07439939
NCT07098065
NCT02417740
NCT04454203
NCT03854071
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions